Intercept Pharmaceuticals (NASDAQ:ICPT) was downgraded by research analysts at Bank of America from a "neutral" rating to an "underperform" rating in a research report issued on Friday, Briefing.com reports. They presently have a $27.00 target price on the biopharmaceutical company's stock, down from their prior target price of $40.00. Bank of America's price target points to a potential downside of 7.66% from the company's current price.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.